2017医药及生命科学趋势（英文版）_16页

2017 Pharmaceuticals and Life Sciences Industry Trends Summary

Core Content

The 2017 Pharmaceuticals and Life Sciences Industry Trends report highlights the transformative changes occurring in the industry due to the rise of the New Health Economy. This new era is characterized by a shift from volume-based to value-based healthcare, driven by factors such as provider consolidation, evolving patient expectations, cost pressures from payors, and the increasing role of rule-based care models.

Main Trends and Challenges

1. The New Health Economy

• Shift to Value-Based Care: The healthcare system is moving towards paying for value rather than volume, making the industry more consumer-facing.
• Patient Engagement: Pharma companies must move beyond traditional top-down models and adopt flexible, interactive approaches to engage with patients.
• Consumer-Centric Approach: Companies need to provide patients with better tools and information to manage their conditions and improve treatment compliance.

2. The Rise of Analytics

• Enterprise Analytics: The industry is undergoing a fundamental shift with the integration of analytics across the value chain.
• Data Utilization: Pharma companies are leveraging cloud-based platforms and advanced data science techniques to analyze large and diverse datasets.
• Strategic Use of Data: The report emphasizes the need for a strategic approach to data analytics, focusing on answering key business questions rather than simply collecting data.
• Benefits of Analytics:
  • R&D: Optimizing clinical trial design by targeting specific patient subpopulations.
  • Commercial: Informing pricing, market access, and treatable patient identification.
  • Risk and Compliance: Enabling real-time monitoring and risk allocation.
  • Supply Chain: Enhancing global supply chain management through predictive analytics.

3. The Value Equation Tipping Point

• Value Assessment: Pharma companies must redefine value to meet the expectations of four stakeholder groups: payors, independent assessors, medical providers, and patients.
• Cost-Effectiveness: Payors and regulatory bodies are increasingly scrutinizing the cost-effectiveness of drugs, leading to challenges in reimbursement and pricing.
• Real-World Evidence: The need for real-world data and outcomes is growing, influencing regulatory and commercial strategies.
• Pay for Performance Models: Companies are exploring models where payment is tied to actual patient outcomes, such as with PCSK9 inhibitors.

Key Information

• Patient Engagement: Companies are developing tools like mobile apps and biosensors to better communicate with patients and monitor treatment outcomes.
• Behavioral Insights: Understanding patient behavior and activation levels is critical for improving compliance and self-care.
• Talent Gap: There is a significant shortage of big data and analytics talent, which could hinder the industry's ability to fully leverage data.
• Innovation and Adaptation: Pharma companies must innovate in areas such as patient engagement, data analytics, and value demonstration to remain competitive.

Conclusion

The report underscores the necessity for pharma companies to adapt to the New Health Economy by embracing data analytics, redefining value, and engaging patients more effectively. These changes are not just about survival but also about shaping the future of patient care and the healthcare landscape as a whole. As the industry evolves, companies that proactively address these challenges will be better positioned to thrive in the new commercial environment.

Authors

• Rick Edmunds: Principal, PwC US
• Gregory Rotz: Principal, PwC US
• Jo Pisani: Partner, PwC UK
• Michael Mentesana: Principal, PwC US
• Doug Strang: Partner, PwC US
• Michael Swanick: Partner, PwC US

Strategy&

Strategy& is a global team of practical strategists committed to helping organizations seize essential advantage through strategic consulting. They offer support in corporate strategy, transformation, and capability building, leveraging 100 years of strategy consulting experience and the PwC network's industry and functional expertise.

Network

PwC operates in 157 countries with over 223,000 professionals committed to delivering quality in assurance, tax, and advisory services. For more information, visit strategyand.pwc.com.